ISG-STS 1001
Standard anthracycline-ifosfamide before surgery beat subtype-tailored chemotherapy, and indirectly showed neoadjuvant chemotherapy helps high-risk sarcoma.
Stopped early: 46-month DFS 62% vs 38%, OS 89% vs 64% favouring standard arm (Lancet Oncol 2017). Long-term follow-up (2020-24) confirmed benefit vs historical controls; established 3 cycles of neoadjuvant anthracycline-ifosfamide for FNCLCC grade 3, >5 cm, deep tumours.
- 89 vs 64 out of 100 alive at 46 months with Epirubicin-ifosfamide compared with Histotype-tailored; 25 more per 100.
- Roughly one extra person helped for every 4 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: High-risk localised soft-tissue sarcoma of extremities/trunk: neoadjuvant epirubicin-ifosfamide vs histotype-tailored chemotherapy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- IdeaA same-week expert second opinion for every rare cancer diagnosis
Shares Histotype-tailored therapy, Alessandro Gronchi, Sarcomas (soft tissue, bone, GIST).
- ProductTrabectedin
Shares Histotype-tailored therapy, Sarcomas (soft tissue, bone, GIST).
- TrialINT-0091 (Ewing sarcoma)
- TrialEuro Ewing 2012
- InstitutionFondazione IRCCS Istituto Nazionale dei Tumori
Shares Alessandro Gronchi, Sarcomas (soft tissue, bone, GIST).
- CancerOsteosarcoma